middl
east
respiratori
syndrom
coronaviru
merscov
lineag
c
betacoronaviru
known
infect
human
annan
et
al
anthoni
et
al
van
boheemen
et
al
similarli
sever
acut
respiratori
syndrom
coronaviru
sarscov
merscov
infect
result
acut
respiratori
distress
syndrom
organ
dysfunct
includ
progress
renal
function
impair
zaki
et
al
accord
world
health
organ
end
august
total
case
laboratori
confirm
least
death
follow
merscov
infect
among
merscov
infect
case
includ
death
report
republ
korea
http
recent
cluster
case
firstli
sprang
outsid
arabian
peninsula
indic
potenti
humantohuman
transmiss
merscov
date
specif
antivir
drug
exist
merscov
infect
support
treatment
mainstay
manag
zumla
et
al
ribavirin
interferon
exhibit
potenti
rhesu
macaqu
model
falzarano
et
al
falzarano
et
al
retrospect
cohort
studi
ribavirin
interferon
therapi
associ
significantli
improv
surviv
day
day
patient
sever
merscov
infect
omrani
et
al
besid
specif
peptid
fusion
inhibitor
merscov
lu
et
al
convalesc
sera
recov
patient
human
monoclon
neutralis
antibodi
jiang
et
al
tang
et
al
ying
et
al
provid
novel
approach
merscov
treatment
howev
data
need
anim
studi
care
done
clinic
studi
zumla
et
al
therefor
develop
prophylact
vaccin
merscov
infect
remain
prioriti
papaneri
et
al
consider
evid
prove
recombin
receptor
bind
domain
rrbd
base
subunit
vaccin
promis
candid
vaccin
sarscov
infect
rrbd
sarscov
spike
protein
induc
strong
neutralis
antibodi
longterm
protect
immun
rabbit
mice
complet
protect
immun
mice
sarscov
infect
zhu
et
al
furthermor
high
titr
neutralis
antibodi
nonhuman
primat
nhp
induc
vaccin
rrbd
sarscov
wang
et
al
experi
use
rrbdbase
subunit
vaccin
sar
could
inform
design
rrbdbase
mer
vaccin
sever
human
neutralis
antibodi
target
rbd
merscov
spike
protein
identifi
librari
tang
et
al
ying
et
al
suggest
rbd
contain
epitop
induc
nab
therefor
may
repres
target
antigen
merscov
group
other
confirm
rrbd
protein
induc
strong
neutralis
antibodi
respons
merscov
infect
mice
rabbit
du
et
al
lan
et
al
et
al
mou
et
al
zhang
et
al
although
rrbd
subunit
vaccin
highli
potent
neutralis
antibodi
tcell
immun
respons
formul
test
higher
anim
model
merscov
challeng
verifi
prophylact
efficaci
gretebeck
subbarao
recent
merscov
infect
diseas
anim
model
develop
agraw
et
al
de
wit
et
al
de
wit
et
al
falzarano
et
al
munster
et
al
pascal
et
al
yao
et
al
zhao
et
al
includ
rhesu
macaqu
model
natur
permiss
merscov
diseas
de
wit
et
al
de
wit
et
al
munster
et
al
yao
et
al
herein
evalu
rrbd
subunit
vaccin
rhesu
macaqu
model
identifi
prophylact
approach
could
use
human
prevent
merscov
infect
anim
studi
conduct
strict
accord
guid
care
use
laboratori
anim
peopl
republ
china
studi
protocol
approv
committe
ethic
anim
experi
chines
centr
diseas
control
prevent
approv
registr
number
compli
reduct
replac
refin
anim
experi
principl
total
rhesu
macaqu
use
experi
procedur
perform
ethyl
ether
anaesthesia
everi
effort
made
minimis
suffer
follow
inocul
merscov
experi
conduct
within
anim
biosafeti
level
facil
merscov
strain
kindli
provid
professor
fouchier
erasmu
medic
centr
netherland
merscov
seed
stock
propag
vero
cell
atcc
number
without
mycoplasma
contamin
maintain
dulbecco
modifi
eagl
medium
dmem
invitrogen
supplement
foetal
bovin
serum
fb
intern
unit
iu
ml
penicillin
streptomycin
cultur
seed
stock
dilut
desir
titr
use
determin
merscov
tissu
cultur
infect
dose
neutralis
antibodi
viru
inocul
assay
merscov
rrbd
protein
contain
fragment
span
residu
prepar
use
baculoviru
express
vector
system
purifi
histrap
hp
superdex
column
ge
healthcar
buck
uk
describ
previous
lan
et
al
lu
et
al
rrbd
protein
admix
aluminium
hydroxid
alum
adjuv
day
immunis
nine
monkey
randomli
assign
highdos
h
lowdos
l
mock
group
tabl
highdos
anim
prime
rrbd
boost
rrbd
admix
mg
alum
adjuv
three
lowdos
anim
prime
rrbd
boost
rrbd
admix
mg
alum
adjuv
control
anim
immunis
pb
mg
alum
adjuv
anim
receiv
second
immunis
week
subsequ
first
assess
longterm
immunolog
respons
interv
second
third
immunis
week
vaccin
formul
administ
intramuscularli
im
two
week
immunis
anim
bled
period
obtain
serum
peripher
blood
mononuclear
cell
pbmc
immunolog
analysi
one
week
final
immunis
anim
transfer
laboratori
follow
adapt
phase
week
nine
immunis
monkey
anaesthetis
inocul
intratrach
merscov
hcovemc
strain
dosag
dilut
dmem
challeng
merscov
monkey
observ
twice
daili
detail
record
clinic
sign
symptom
morbid
mortal
includ
natur
onset
sever
durat
gross
visibl
chang
chest
xray
perform
day
pre
day
postinocul
dpi
merscov
nasal
oropharyng
rectal
swab
collect
time
point
three
day
challeng
merscov
monkey
euthan
tissu
specimen
includ
lung
trachea
spleen
kidney
collect
variou
patholog
virolog
immunolog
test
schemat
vaccin
schedul
biolog
specimen
collect
timelin
display
fig
anim
bled
period
throughout
studi
fig
deriv
serum
antibodi
detect
endpoint
antirbd
igg
antibodi
titr
determin
elisa
describ
previous
lan
et
al
merscov
pseudoviru
system
conduct
within
biosafeti
facil
report
previous
lan
et
al
rel
light
unit
determin
immedi
use
gaomax
luminomet
promega
experi
perform
triplic
pseudoviru
inhibit
pi
rate
calcul
follow
relativeluciferaseunitsofmocksera
viru
neutralis
assay
conduct
vero
cell
briefli
sera
dilut
twofold
mix
viru
incub
h
quadrupl
thereaft
virusserum
mixtur
ad
vero
cell
previous
seed
inocul
plate
incub
incub
day
follow
cytopath
effect
cpe
viru
observ
microscop
magnif
test
repeat
twice
independ
evalu
antigenspecif
tcell
respons
induc
rrbd
protein
immunis
monkey
elispot
assay
perform
describ
previous
wen
et
al
pbmc
isol
edtatr
blood
elispot
assay
carri
accord
manufactur
instruct
briefli
cell
per
well
stimul
pool
peptid
overlap
amino
acid
span
rbd
protein
merscov
final
concentr
pvdf
membranebottom
plate
precoat
antimonkey
captur
antibodi
set
neg
control
well
compris
media
includ
plate
stimul
h
cell
detect
stain
membran
detect
antibodi
follow
streptavidinhorseradish
peroxidas
develop
tmb
substrat
solut
result
present
spotform
cell
per
pbmc
valu
report
mean
test
well
minu
mean
negativecontrol
well
total
rna
isol
individu
sampl
use
rneasi
mini
kit
qiagen
revers
transcript
reaction
perform
use
superscript
iii
first
strand
synthesi
kit
invitrogen
describ
previous
yao
et
al
deriv
complementari
dna
cdna
cdna
sampl
store
use
qrtpcr
target
upe
describ
previous
corman
et
al
even
though
qrtpcr
consid
highli
sensit
assay
detect
viral
nucleic
acid
assay
viral
isol
absolut
necess
detect
real
viral
replic
end
tissu
homogenis
final
suspens
dmem
clarifi
lowspe
centrifug
g
min
swab
sampl
immers
dmem
vortex
clarifi
lowspe
centrifug
g
min
viru
titr
determin
vero
cell
monolay
grown
plate
describ
previous
yao
et
al
brief
vero
cell
seed
plate
incub
overnight
incub
onehundr
microlit
serial
dilut
suspens
ad
well
quadrupl
viru
allow
adsorb
cell
h
adsorpt
viral
inocula
remov
dmem
fb
ad
well
plate
incub
incub
day
follow
cpe
observ
microscop
magnif
viru
titr
express
specimen
calcul
method
necropsi
perform
anim
accord
standard
protocol
lung
trachea
spleen
kidney
tissu
sampl
collect
histopatholog
immunohistochem
examin
procedur
perform
use
fix
neutral
buffer
formalin
embed
paraffin
sequenti
section
thick
stain
haematoxylin
eosin
prior
examin
light
microscopi
immunohistochemistri
analysi
stain
method
includ
antigen
retriev
citrat
buffer
rabbitserumderiv
polyclon
antibodi
nucleoprotein
sino
biolog
inc
cat
dilut
incub
section
secondari
antibodi
use
goat
antirabbit
zsgbbio
cat
final
result
evalu
use
light
microscopi
acquir
subject
result
differ
multipl
site
lung
trachea
spleen
kidney
tissu
sampl
collect
histopatholog
immunohistochemistri
analysi
final
quantit
slide
per
anim
use
assess
effect
impact
immun
anim
statist
analys
conduct
use
oneway
anova
bonferroni
posttest
via
spss
window
softwar
packag
ver
spss
inc
chicago
il
usa
unpair
twotail
student
test
use
compar
mean
differ
group
valu
p
taken
indic
statist
signific
result
express
mean
sd
figur
render
use
prism
softwar
packag
graphpad
softwar
ca
usa
assess
humor
immun
respons
rrbd
vaccin
rhesu
macaqu
total
antimerscov
rbd
igg
antibodi
titr
determin
elisa
low
titr
igg
serum
sampl
prime
vaccin
detect
possibl
due
nonspecif
respons
igg
titr
highdos
group
increas
significantli
p
first
vaccin
fig
achiev
highest
titr
rbdspecif
igg
week
second
immunis
sera
igg
titr
lowdos
group
increas
p
second
immunis
almost
level
highdos
group
rbdspecif
igg
sera
immunis
rhesu
macaqu
preserv
least
week
without
obviou
declin
addit
igg
titr
increas
rapidli
subsequ
boost
increas
igg
titr
particularli
mark
lowdos
group
circul
neutralis
antibodi
titr
monitor
simultan
pseudoviru
system
neutralis
antibodi
detect
second
vaccin
pseudoviru
inhibit
rate
neutralis
antibodi
titr
sera
week
second
vaccin
low
highdos
group
respect
fig
nonspecif
neutralis
antibodi
titr
mock
group
detect
neutralis
antibodi
rrbd
immunis
monkey
persist
least
week
neutralis
antibodi
titr
sera
low
highdos
group
respect
fig
encouragingli
follow
next
boost
immunis
neutralis
antibodi
titr
high
fig
almost
ident
week
second
vaccin
week
detect
time
point
highdos
rrbd
induc
higher
neutralis
antibodi
titr
pseudoviru
system
neutralis
antibodi
titr
sera
follow
rrbd
vaccin
also
detect
vero
cell
hcovemc
strain
merscov
neutralis
antibodi
titr
sera
rrbd
immunis
monkey
week
low
highdos
group
respect
fig
week
neutralis
antibodi
titr
decreas
slightli
follow
subsequ
immunis
boost
neutralis
antibodi
day
pre
merscov
challeng
almost
high
week
detect
time
point
nonspecif
neutralis
antibodi
titr
mock
group
lower
equal
assess
tcell
immun
respons
rhesu
macaqu
pbmc
deriv
differ
time
follow
rrbd
immunis
stimul
overlap
synthet
peptid
rbd
elispot
analys
conduct
immunis
rrbd
protein
induc
antigen
specif
tcell
addit
highdos
rrbd
induc
significantli
higher
level
tcell
fig
follow
merscov
challeng
monkey
observ
twice
daili
detail
record
clinic
sign
symptom
morbid
mortal
includ
natur
onset
sever
durat
gross
visibl
chang
challeng
monkey
includ
rrbdimmunis
anim
drastic
decreas
water
intak
infect
monkey
exhibit
excess
weight
loss
die
experi
monitor
sign
pneumonia
merscov
challeng
anim
xray
examin
perform
day
pre
day
merscov
inocul
radiographi
reveal
monkey
neg
pneumonia
merscov
challeng
day
mock
group
anim
local
interstiti
inflamm
detect
dpi
pneumonia
diffus
adjac
pulmonari
lobe
dpi
pneumonia
gener
highdos
group
delay
dpi
infiltr
confin
singl
lobe
fig
although
pneumonia
detect
lowdos
monkey
dpi
infiltr
interstiti
inflamm
less
sever
compar
mock
group
gross
patholog
challeng
anim
investig
necropsi
perform
dpi
follow
euthanasia
lung
mock
group
anim
congest
palpabl
nodul
fig
dark
red
discolour
multifoc
consolid
consist
interstiti
pneumonia
indic
xray
examin
contrast
haemorrhag
necrosi
shown
black
circl
rrbdgroup
smaller
high
low
dose
immun
fig
investig
pneumonia
follow
merscov
infect
histopatholog
immunohistochem
analys
conduct
elucid
effect
rrbd
vaccin
control
monkey
lung
tissu
exhibit
moder
lesion
fig
abund
alveolar
oedema
fibrin
format
hyalin
member
smalltomoder
degre
macrophag
fibrou
infiltr
fig
contrast
mildtomoderates
lesion
observ
lung
tissu
rrbdimmunis
monkey
fig
infiltr
inflammatori
cell
also
detect
trachea
mock
group
monkey
fig
although
inflammatori
cell
infiltr
impair
epithelium
tunica
mucosa
bronchiorum
also
found
rrbd
vaccin
group
fig
lesion
allevi
compar
control
group
glomerular
capsul
expans
observ
kidney
challeng
monkey
data
shown
consid
incident
clinic
nonsignific
find
specif
patholog
chang
observ
spleen
immunis
monkey
data
shown
viral
antigen
use
polyclon
antibodi
nucleoprotein
found
ihc
lung
fig
trachea
fig
f
monkey
specif
antigen
detect
kidney
challeng
monkey
data
shown
qrtpcr
use
upe
gene
primer
specif
merscov
conduct
determin
viral
load
serum
swab
tissu
includ
lung
trachea
kidney
viral
rna
detect
throat
nasal
rectal
swab
fig
dpi
dpi
similarli
viral
rna
lung
tracheal
tissu
homogen
detect
dpi
fig
compar
control
monkey
rrbd
vaccin
decreas
p
viral
load
oronasopharynx
swab
lung
trachea
viral
rna
detect
kidney
serum
challeng
monkey
viru
titr
variou
tissu
swab
immunis
anim
determin
endpoint
titrat
vero
cell
viral
load
lung
trachea
control
monkey
high
respect
tabl
rrbdimmunis
monkey
could
isol
merscov
lung
although
merscov
could
isol
two
six
rrbdimmunis
monkey
viru
titr
lower
vs
mock
group
mer
viru
emerg
consid
threat
global
public
health
develop
effect
vaccin
import
control
merscov
infect
date
virusvector
vaccin
recombin
modifi
vaccinia
viru
ankara
mva
express
fulllength
merscov
spike
protein
mvamerss
recombin
adenovir
vector
encod
fulllength
merscov
protein
extracellular
domain
protein
develop
test
abil
induc
virusneutralis
antibodi
mice
kim
et
al
song
et
al
volz
et
al
besid
rrbd
subunit
vaccin
confer
highli
potent
neutralis
antibodi
tcell
immun
respons
mice
zhang
et
al
howev
studi
assess
respons
merscov
challeng
verifi
efficaci
due
lack
anim
model
exampl
mice
coleman
et
al
scobey
et
al
hamster
de
wit
et
al
de
wit
et
al
ferret
raj
et
al
prove
infect
merscov
natur
recent
small
anim
model
merscov
infect
develop
transduc
mice
adenoviru
vector
express
human
zhao
et
al
howev
merscov
infect
model
highli
depend
transduct
cell
level
express
adenoviru
vector
therefor
necessarili
reflect
natur
diseas
process
falzarano
et
al
recent
transgen
mous
model
merscov
publish
agraw
et
al
howev
model
cell
mous
express
human
kind
nonphysiolog
express
pattern
result
extens
brain
infect
merscov
rapidli
succumb
infect
mice
moreov
novel
human
mous
model
merscov
infect
develop
though
mice
acquir
routin
technolog
pascal
et
al
encouragingli
rhesu
macaqu
model
natur
permiss
merscov
diseas
close
mimic
diseas
cours
human
patient
de
wit
et
al
de
wit
et
al
munster
et
al
yao
et
al
furthermor
effect
ribavirin
treatment
evalu
model
falzarano
et
al
falzarano
et
al
therefor
herein
assess
rrbd
vaccin
efficaci
nhp
model
similar
rrbd
protein
sarscov
induc
high
titr
protect
antirbd
antibodi
respons
nhp
wang
et
al
rrbd
vaccin
merscov
induc
effect
igg
neutralis
antibodi
rhesu
macaqu
model
besid
induc
igg
neutralis
antibodi
maintain
least
week
without
obviou
attenu
follow
subsequ
boost
antibodi
titr
reach
almost
previou
peak
level
evid
differ
induct
humor
immun
high
low
dose
group
howev
highdos
vaccin
induc
stronger
tcell
respons
lowdos
vaccin
follow
merscov
challeng
rhesu
macaqu
exhibit
transient
lower
respiratori
tract
infect
accord
previou
report
de
wit
et
al
de
wit
et
al
munster
et
al
yao
et
al
although
infect
also
detect
rrbdimmunis
anim
clinic
sign
allevi
patholog
chang
lung
trachea
rrbdimmunis
anim
indic
reduc
fulli
absent
lesion
use
qrtpcr
assay
viral
load
lung
trachea
oropharyng
swab
rrbd
vaccin
group
decreas
furthermor
rrbdimmunis
monkey
could
isol
merscov
lung
viral
load
lung
trachea
mock
monkey
high
respect
consist
result
immun
elicit
high
low
dose
rrbd
vaccin
protect
merscov
infect
monkey
could
contribut
humor
immun
especi
neutralis
antibodi
rather
cellular
mediat
immun
although
rrbd
vaccin
allevi
pneumonia
decreas
viral
load
rhesu
macaqu
upon
challeng
merscov
studi
prevent
infect
merscov
complet
data
interpret
caution
first
rhesu
macaqu
model
mimic
merscov
infect
inevit
limit
present
previou
report
merscov
challeng
rhesu
macaqu
model
result
transient
infect
lower
respiratori
tract
de
wit
et
al
de
wit
et
al
munster
et
al
yao
et
al
sever
even
lethal
diseas
cours
frequent
associ
human
case
observ
herein
van
den
brand
et
al
therefor
prophylact
effect
rrbd
vaccin
fulli
demonstr
model
second
merscov
challeng
trachea
bypass
natur
entri
site
nasal
mucosa
laryng
area
pharynx
show
crucial
region
mucos
immun
sato
kiyono
bypass
mucos
immun
first
defenc
lot
infecti
diseas
includ
merscov
neutra
k
p
third
challeng
dose
markedli
greater
typic
merscov
exposur
human
recent
progress
lethal
pneumonia
observ
merscov
challeng
common
marmoset
model
falzarano
et
al
infect
anim
develop
viremia
total
rna
sequenc
demonstr
induct
immun
inflammatori
pathway
falzarano
et
al
therefor
marmoset
model
correspond
close
diseas
cours
human
allow
clearer
discrimin
success
treat
control
anim
therefor
protect
efficaci
vaccin
candid
remain
test
suitabl
diseas
model
eg
common
marmoset
human
knowledg
studi
repres
first
evalu
protect
efficaci
candid
subunit
antigen
merscov
nonhuman
primat
observ
sustain
signific
antibodi
neutralis
tcell
immun
rhesu
macaqu
respons
rrbd
merscov
besid
rrbd
vaccin
allevi
pneumonia
decreas
viral
load
rhesu
macaqu
upon
challeng
merscov
summari
result
provid
insight
immunogen
rrbd
subunit
vaccin
merscov
data
indic
subunit
rrbd
vaccin
confer
partial
protect
merscov
challeng
rhesu
macaqu
could
use
futur
merscov
vaccin
trial
prevent
strategi
author
declar
compet
interest
exist
wjt
gfg
cq
conceiv
project
design
research
jml
yd
hc
ww
conduct
major
vaccin
experi
gwl
gfg
provid
rbd
protein
final
edit
manuscript
yfi
wd
llb
qw
assist
merscov
challeng
protect
studi
facil
jml
yfi
cq
wjt
wrote
manuscript
author
review
approv
manuscript
work
support
grant
megaproject
infecti
diseas
research
china
megaproject
novel
drug
discoveri
china
nation
natur
scienc
fund
china
nation
program
china
funder
role
studi
design
data
collect
analysi
decis
publish
prepar
manuscript
